Magaldrate
Systematic (IUPAC) name | |
---|---|
Magnesium aluminate monohydrate | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a682683 |
| |
| |
Oral | |
Pharmacokinetic data | |
Bioavailability | Negligible |
Metabolism | Nil |
Excretion | Fecal and renal |
Identifiers | |
1317-26-6 | |
A02AD02 A02AF01 (combination with antiflatulents) | |
PubChem | CID 6336542 |
ChemSpider | 4891688 |
UNII | 6V88E24N5T |
Chemical data | |
Formula | AlMg2(OH)7·H2O |
212.66 g/mol | |
| |
(what is this?) (verify) |
Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.
Available forms
Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[1]
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
Brand names
The drug is sold with the following brand names:Maganta plus (Square pharma,Bangladesh) Digecid Plus (Beximco Pharma, Bangladesh), Marlox Plus (Incepta pharma Bangladesh), Gastid (SK+F, Bangladesh), Novelta (Bangladesh), Gadral (Italy); Magaltop (Italy); Magralibi (Italy); Mylanta (Australia); Riopan (Argentina, Austria, Brazil, Egypt, Germany, Italy, Mexico, Belgium, Switzerland, Greece).
References
- ↑ Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.
|